Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(05): 496-500
DOI: 10.1055/s-0041-1736432
Case Report with Review of Literature

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Nikita Oza‡   *
1   Department of Histopathology, SRL Diagnostics – Centre of Excellence, Goregaon West, Mumbai, Maharashtra, India
,
Krishnakumar Rathnam‡   *
2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
,
Gujral Sumeet
3   Department of Pathology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India
,
Susan R. Honey 
2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
,
S. V. Saju 
2   Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
,
Kane Shubhada
1   Department of Histopathology, SRL Diagnostics – Centre of Excellence, Goregaon West, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm for which there are no effective therapies. We present a 70-year-old male patient with multiple reddish painless, nonpruritic, and nonpedunculated nodules over the trunk, forearm, and thighs for a duration of 3 months. The nodules measured 0.5 to 2 cm in diameter. The peripheral smear findings were within normal limits. Excision biopsy was performed. Histomorphology and immunohistochemistry (CD123, CD 56, CD4, HLA-DR, CD43, and CD68) confirmed the diagnosis of BPDCN. Findings of marrow aspiration, biopsy and imaging studies were within normal limits. Patient demonstrated a good response with complete disappearance of all nodules by initial 2 weeks of therapy with a modified Berlin–Frankfurt–Munster (BFM) acute lymphoblastic leukemia (ALL) protocol and has completed 8 doses (LSAP [lincosamides, streptogramins A and pleuromutilins chemotherapy], 5,000 units/m2). The patient tolerated protocol extremely well.

Keywords

blastic plasmacytoid dendritic cell neoplasm - chemotherapy - stem cell therapy - targeted therapy

Ethics Statement

The authors hereby declare that Institutional Ethics Committee did not mandate IEC review for this study. The collection of data from electronic medical record (EMR) and laboratory reports do not require an informed consent form as per the hospital's standard operating procedures.


* Authors have equally contributed for writing, review and editing the case report.




Publication History

Article published online:
05 December 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sapienza MR, Pileri A, Derenzini E. et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers (Basel) 2019; 11 (05) 595
    CrossrefPubMedGoogle Scholar
  • 2 Facchetti F, Pileri SA, Agostinelli C. et al. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2009; 94 (02) 285-288
    CrossrefPubMedGoogle Scholar
  • 3 Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?. Br J Haematol 2007; 136 (04) 539-548
    CrossrefPubMedGoogle Scholar
  • 4 Pagano L, Valentini CG, Pulsoni A. et al; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013; 98 (02) 239-246
    CrossrefPubMedGoogle Scholar
  • 5 Swerdlow SH, Campo E, Harris NL. et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Revised 4th ed. Vol 2.. Lyon, France: International Agency for Research on Cancer; 2017
    Google Scholar
  • 6 Sapienza MR, Abate F, Melle F. et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica 2019; 104 (04) 729-737
    CrossrefPubMedGoogle Scholar
  • 7 Sapienza MR, Fuligni F, Agostinelli C. et al; AIRC 5xMille consortium ‘Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 2014; 28 (08) 1606-1616
    CrossrefPubMedGoogle Scholar
  • 8 Demiröz AS, Demirkesen C, Salihoğlu A, Tüzüner N. Blastic plasmacytoid dendritic cell neoplasia: a single center experience. Turk J Haematol 2020; 37 (01) 48-52
    PubMedGoogle Scholar
  • 9 Bekkenk MW, Jansen PM, Meijer CJLM, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15 (07) 1097-1108
    CrossrefPubMedGoogle Scholar
  • 10 Suzuki R, Nakamura S, Suzumiya J. et al; NK-cell Tumor Study Group. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005; 104 (05) 1022-1031
    CrossrefPubMedGoogle Scholar
  • 11 Assaf C, Gellrich S, Whittaker S. et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60 (09) 981-989
    CrossrefPubMedGoogle Scholar
  • 12 Cota C, Vale E, Viana I. et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34 (01) 75-87
    CrossrefPubMedGoogle Scholar
  • 13 Rauh MJ, Rahman F, Good D. et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review. Leuk Res 2012; 36 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 14 Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 2009; 16 (06) 392-404
    CrossrefPubMedGoogle Scholar
  • 15 Petrella T, Facchetti F. Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009?. Autoimmunity 2010; 43 (03) 210-214
    CrossrefPubMedGoogle Scholar
  • 16 Lucioni M, Novara F, Fiandrino G. et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 2011; 118 (17) 4591-4594
    CrossrefPubMedGoogle Scholar
  • 17 Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch Pathol Lab Med 2014; 138 (04) 564-569
    CrossrefPubMedGoogle Scholar
  • 18 Swerdlow S, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.. Lyon, France: IARC; 2008
    Google Scholar
  • 19 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    CrossrefPubMedGoogle Scholar
  • 20 Deotare U, Yee KWL, Le LW. et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and hyperCVAD therapy. Am J Hematol 2016; 91 (03) 283-286
    CrossrefPubMedGoogle Scholar
  • 21 Deotare U, Kim DD, Michelis FV, Lipton JH, Lipton JH. Allogeneic hematopoietic stem cell transplantions in blastic plasmacytoid dendritic cell neoplasm in first complete remission: an effective therapy for a rare disease. Leuk Lymphoma 2016; 57 (08) 1942-1944
    CrossrefPubMedGoogle Scholar
  • 22 Gruson B, Vaida I, Merlusca L. et al. L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 2013; 163 (04) 543-545
    CrossrefPubMedGoogle Scholar
  • 23 Gilis L, Lebras L, Bouafia-Sauvy F. et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma 2012; 53 (08) 1633-1637
    CrossrefPubMedGoogle Scholar
  • 24 Reimer P, Rüdiger T, Kraemer D. et al. What is CD4+CD56+ malignancy and how should it be treated?. Bone Marrow Transplant 2003; 32 (07) 637-646
    CrossrefPubMedGoogle Scholar
  • 25 Leitenberger JJ, Berthelot CN, Polder KD. et al. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 2008; 58 (03) 480-484
    CrossrefPubMedGoogle Scholar
  • 26 DiNardo CD, Pratz K, Pullarkat V. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133 (01) 7-17
    CrossrefPubMedGoogle Scholar
  • 27 Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, De Padova N, Becker PS. Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 2017; 92 (05) E75-E77
    CrossrefPubMedGoogle Scholar
  • 28 Khwaja R, Daly A, Wong M, Mahé E, Cerquozzi S, Owen C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma 2016; 57 (11) 2720-2722
    CrossrefPubMedGoogle Scholar
  • 29 Frankel AE, Woo JH, Ahn C. et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014; 124 (03) 385-392
    CrossrefPubMedGoogle Scholar